The United Laboratories International Holdings (HK:3933) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The United Laboratories International Holdings has announced that its Ceftazidime for Injection has passed the quality and efficacy consistency evaluation, strengthening its position in the anti-infective market. This product, a third-generation cephalosporin antibiotic, is used for a variety of infections and is included in China’s National Essential Drug List. The approval supports the company’s ongoing commitment to developing innovative healthcare solutions.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.